nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—ALK—lymphatic system cancer	0.617	1	CbGaD
Bosutinib—BTK—Mitoxantrone—lymphatic system cancer	0.24	0.884	CbGbCtD
Bosutinib—ABCB1—Mitoxantrone—lymphatic system cancer	0.00652	0.024	CbGbCtD
Bosutinib—CYP3A4—Cytarabine—lymphatic system cancer	0.00567	0.0209	CbGbCtD
Bosutinib—CYP3A4—Teniposide—lymphatic system cancer	0.00559	0.0206	CbGbCtD
Bosutinib—ABCB1—Vincristine—lymphatic system cancer	0.00449	0.0165	CbGbCtD
Bosutinib—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00391	0.0144	CbGbCtD
Bosutinib—ABCB1—Methotrexate—lymphatic system cancer	0.00272	0.01	CbGbCtD
Bosutinib—CYP3A4—Vincristine—lymphatic system cancer	0.00269	0.0099	CbGbCtD
Bosutinib—CSF1R—Differentiation Pathway—ALK—lymphatic system cancer	0.00131	0.0879	CbGpPWpGaD
Bosutinib—SIK1—Circadian rythm related genes—PROX1—lymphatic system cancer	0.00102	0.0683	CbGpPWpGaD
Bosutinib—CSNK1A1—FoxO family signaling—BCL6—lymphatic system cancer	0.00101	0.0678	CbGpPWpGaD
Bosutinib—FES—IL4-mediated signaling events—BCL6—lymphatic system cancer	0.00101	0.0673	CbGpPWpGaD
Bosutinib—CDK2—FoxO family signaling—BCL6—lymphatic system cancer	0.000861	0.0577	CbGpPWpGaD
Bosutinib—LOC400927-CSNK1E—Circadian rythm related genes—PROX1—lymphatic system cancer	0.000831	0.0557	CbGpPWpGaD
Bosutinib—CSNK1E—FoxO family signaling—BCL6—lymphatic system cancer	0.000818	0.0548	CbGpPWpGaD
Bosutinib—ERBB3—Podofilox—Teniposide—lymphatic system cancer	0.000637	0.177	CbGdCrCtD
Bosutinib—MAP4K4—Direct p53 effectors—BCL6—lymphatic system cancer	0.000625	0.0419	CbGpPWpGaD
Bosutinib—SYK—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000598	0.04	CbGpPWpGaD
Bosutinib—CDK2—Vinblastine—Vincristine—lymphatic system cancer	0.000574	0.16	CbGdCrCtD
Bosutinib—MAP4K1—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000566	0.0379	CbGpPWpGaD
Bosutinib—RPS6KB1—IL4-mediated signaling events—BCL6—lymphatic system cancer	0.000536	0.0359	CbGpPWpGaD
Bosutinib—BTK—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000474	0.0317	CbGpPWpGaD
Bosutinib—CAMK2G—Azacitidine—Fludarabine—lymphatic system cancer	0.000437	0.122	CbGdCrCtD
Bosutinib—CSNK1E—Circadian rythm related genes—PROX1—lymphatic system cancer	0.000437	0.0292	CbGpPWpGaD
Bosutinib—CHEK2—Podofilox—Teniposide—lymphatic system cancer	0.00043	0.12	CbGdCrCtD
Bosutinib—CAMK2G—Azacitidine—Cytarabine—lymphatic system cancer	0.000413	0.115	CbGdCrCtD
Bosutinib—CHEK2—Vindesine—Vincristine—lymphatic system cancer	0.000406	0.113	CbGdCrCtD
Bosutinib—BLK—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000394	0.0264	CbGpPWpGaD
Bosutinib—EPHA2—Direct p53 effectors—BCL6—lymphatic system cancer	0.000386	0.0259	CbGpPWpGaD
Bosutinib—Dehydration—Vincristine—lymphatic system cancer	0.000341	0.00367	CcSEcCtD
Bosutinib—Oedema—Teniposide—lymphatic system cancer	0.000335	0.00361	CcSEcCtD
Bosutinib—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.000335	0.00361	CcSEcCtD
Bosutinib—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.000334	0.0036	CcSEcCtD
Bosutinib—Anaemia—Fludarabine—lymphatic system cancer	0.000334	0.0036	CcSEcCtD
Bosutinib—Infection—Teniposide—lymphatic system cancer	0.000333	0.00359	CcSEcCtD
Bosutinib—Dehydration—Mitoxantrone—lymphatic system cancer	0.000332	0.00358	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00033	0.00356	CcSEcCtD
Bosutinib—Thrombocytopenia—Teniposide—lymphatic system cancer	0.000328	0.00354	CcSEcCtD
Bosutinib—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.000326	0.00351	CcSEcCtD
Bosutinib—Malaise—Fludarabine—lymphatic system cancer	0.000326	0.00351	CcSEcCtD
Bosutinib—Leukopenia—Fludarabine—lymphatic system cancer	0.000323	0.00348	CcSEcCtD
Bosutinib—Pruritus—Mechlorethamine—lymphatic system cancer	0.000322	0.00347	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.000321	0.00346	CcSEcCtD
Bosutinib—Pleural effusion—Methotrexate—lymphatic system cancer	0.00032	0.00345	CcSEcCtD
Bosutinib—Hepatotoxicity—Methotrexate—lymphatic system cancer	0.000317	0.00342	CcSEcCtD
Bosutinib—Cough—Fludarabine—lymphatic system cancer	0.000315	0.0034	CcSEcCtD
Bosutinib—Pancytopenia—Carmustine—lymphatic system cancer	0.000315	0.0034	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.000315	0.00339	CcSEcCtD
Bosutinib—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000311	0.00335	CcSEcCtD
Bosutinib—Neutropenia—Carmustine—lymphatic system cancer	0.00031	0.00334	CcSEcCtD
Bosutinib—Arthralgia—Fludarabine—lymphatic system cancer	0.000307	0.00331	CcSEcCtD
Bosutinib—Myalgia—Fludarabine—lymphatic system cancer	0.000307	0.00331	CcSEcCtD
Bosutinib—Discomfort—Fludarabine—lymphatic system cancer	0.000304	0.00327	CcSEcCtD
Bosutinib—Pancytopenia—Vincristine—lymphatic system cancer	0.000301	0.00324	CcSEcCtD
Bosutinib—Dyspnoea—Teniposide—lymphatic system cancer	0.000299	0.00322	CcSEcCtD
Bosutinib—Pneumonia—Carmustine—lymphatic system cancer	0.000297	0.00321	CcSEcCtD
Bosutinib—Neutropenia—Vincristine—lymphatic system cancer	0.000296	0.00319	CcSEcCtD
Bosutinib—Oedema—Fludarabine—lymphatic system cancer	0.000295	0.00318	CcSEcCtD
Bosutinib—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.000295	0.00318	CcSEcCtD
Bosutinib—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.000293	0.00316	CcSEcCtD
Bosutinib—Infection—Fludarabine—lymphatic system cancer	0.000293	0.00316	CcSEcCtD
Bosutinib—Decreased appetite—Teniposide—lymphatic system cancer	0.000292	0.00314	CcSEcCtD
Bosutinib—Renal failure—Carmustine—lymphatic system cancer	0.000291	0.00313	CcSEcCtD
Bosutinib—Vomiting—Mechlorethamine—lymphatic system cancer	0.000289	0.00312	CcSEcCtD
Bosutinib—Nervous system disorder—Fludarabine—lymphatic system cancer	0.000289	0.00312	CcSEcCtD
Bosutinib—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000289	0.00311	CcSEcCtD
Bosutinib—Neutropenia—Mitoxantrone—lymphatic system cancer	0.000288	0.00311	CcSEcCtD
Bosutinib—Rash—Mechlorethamine—lymphatic system cancer	0.000287	0.00309	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.000287	0.00309	CcSEcCtD
Bosutinib—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000287	0.00309	CcSEcCtD
Bosutinib—Pneumonia—Vincristine—lymphatic system cancer	0.000284	0.00306	CcSEcCtD
Bosutinib—MAP3K7—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000283	0.019	CbGpPWpGaD
Bosutinib—Pneumonia—Mitoxantrone—lymphatic system cancer	0.000277	0.00298	CcSEcCtD
Bosutinib—Feeling abnormal—Teniposide—lymphatic system cancer	0.000276	0.00298	CcSEcCtD
Bosutinib—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000274	0.00296	CcSEcCtD
Bosutinib—Renal failure—Mitoxantrone—lymphatic system cancer	0.00027	0.00291	CcSEcCtD
Bosutinib—Nausea—Mechlorethamine—lymphatic system cancer	0.00027	0.00291	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000269	0.00289	CcSEcCtD
Bosutinib—Urticaria—Teniposide—lymphatic system cancer	0.000266	0.00287	CcSEcCtD
Bosutinib—Abdominal pain—Teniposide—lymphatic system cancer	0.000265	0.00286	CcSEcCtD
Bosutinib—Body temperature increased—Teniposide—lymphatic system cancer	0.000265	0.00286	CcSEcCtD
Bosutinib—Dyspnoea—Fludarabine—lymphatic system cancer	0.000263	0.00283	CcSEcCtD
Bosutinib—Oedema peripheral—Carmustine—lymphatic system cancer	0.000262	0.00282	CcSEcCtD
Bosutinib—Connective tissue disorder—Carmustine—lymphatic system cancer	0.000261	0.00281	CcSEcCtD
Bosutinib—ERBB3—Vinblastine—Vincristine—lymphatic system cancer	0.000261	0.0726	CbGdCrCtD
Bosutinib—MAP3K7—DNA Damage Response (only ATM dependent)—BCL6—lymphatic system cancer	0.000258	0.0173	CbGpPWpGaD
Bosutinib—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.000257	0.00277	CcSEcCtD
Bosutinib—Decreased appetite—Fludarabine—lymphatic system cancer	0.000256	0.00276	CcSEcCtD
Bosutinib—CHEK2—Vinorelbine—Vincristine—lymphatic system cancer	0.000256	0.0714	CbGdCrCtD
Bosutinib—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000254	0.00274	CcSEcCtD
Bosutinib—Fatigue—Fludarabine—lymphatic system cancer	0.000254	0.00274	CcSEcCtD
Bosutinib—Pain—Fludarabine—lymphatic system cancer	0.000252	0.00272	CcSEcCtD
Bosutinib—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00025	0.0027	CcSEcCtD
Bosutinib—Respiratory failure—Methotrexate—lymphatic system cancer	0.000249	0.00269	CcSEcCtD
Bosutinib—Connective tissue disorder—Vincristine—lymphatic system cancer	0.000249	0.00268	CcSEcCtD
Bosutinib—Urethral disorder—Vincristine—lymphatic system cancer	0.000248	0.00268	CcSEcCtD
Bosutinib—MAP2K2—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000247	0.0166	CbGpPWpGaD
Bosutinib—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000247	0.00266	CcSEcCtD
Bosutinib—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000246	0.00265	CcSEcCtD
Bosutinib—Anaemia—Bleomycin—lymphatic system cancer	0.000245	0.00264	CcSEcCtD
Bosutinib—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000243	0.00262	CcSEcCtD
Bosutinib—Asthenia—Teniposide—lymphatic system cancer	0.000241	0.00259	CcSEcCtD
Bosutinib—Malaise—Bleomycin—lymphatic system cancer	0.000239	0.00257	CcSEcCtD
Bosutinib—Pruritus—Teniposide—lymphatic system cancer	0.000237	0.00256	CcSEcCtD
Bosutinib—Leukopenia—Bleomycin—lymphatic system cancer	0.000237	0.00255	CcSEcCtD
Bosutinib—LYN—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000236	0.0158	CbGpPWpGaD
Bosutinib—Cardiac disorder—Vincristine—lymphatic system cancer	0.000235	0.00254	CcSEcCtD
Bosutinib—Body temperature increased—Fludarabine—lymphatic system cancer	0.000233	0.00251	CcSEcCtD
Bosutinib—FYN—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000233	0.0156	CbGpPWpGaD
Bosutinib—MAP2K1—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000231	0.0155	CbGpPWpGaD
Bosutinib—Malnutrition—Carmustine—lymphatic system cancer	0.000231	0.00249	CcSEcCtD
Bosutinib—Cough—Bleomycin—lymphatic system cancer	0.000231	0.00249	CcSEcCtD
Bosutinib—Diarrhoea—Teniposide—lymphatic system cancer	0.000229	0.00247	CcSEcCtD
Bosutinib—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000228	0.00246	CcSEcCtD
Bosutinib—Chest pain—Bleomycin—lymphatic system cancer	0.000225	0.00243	CcSEcCtD
Bosutinib—Myalgia—Bleomycin—lymphatic system cancer	0.000225	0.00243	CcSEcCtD
Bosutinib—Back pain—Carmustine—lymphatic system cancer	0.000224	0.00241	CcSEcCtD
Bosutinib—HCK—Host Interactions of HIV factors—NPM1—lymphatic system cancer	0.000223	0.0149	CbGpPWpGaD
Bosutinib—Discomfort—Bleomycin—lymphatic system cancer	0.000223	0.0024	CcSEcCtD
Bosutinib—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000216	0.00233	CcSEcCtD
Bosutinib—Oedema—Bleomycin—lymphatic system cancer	0.000216	0.00233	CcSEcCtD
Bosutinib—Infection—Bleomycin—lymphatic system cancer	0.000215	0.00231	CcSEcCtD
Bosutinib—ABL1—DNA Damage Response (only ATM dependent)—BCL6—lymphatic system cancer	0.000214	0.0143	CbGpPWpGaD
Bosutinib—Anaemia—Carmustine—lymphatic system cancer	0.000214	0.0023	CcSEcCtD
Bosutinib—Back pain—Vincristine—lymphatic system cancer	0.000213	0.0023	CcSEcCtD
Bosutinib—Vomiting—Teniposide—lymphatic system cancer	0.000213	0.0023	CcSEcCtD
Bosutinib—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000212	0.00228	CcSEcCtD
Bosutinib—Asthenia—Fludarabine—lymphatic system cancer	0.000211	0.00228	CcSEcCtD
Bosutinib—Rash—Teniposide—lymphatic system cancer	0.000211	0.00228	CcSEcCtD
Bosutinib—Dermatitis—Teniposide—lymphatic system cancer	0.000211	0.00228	CcSEcCtD
Bosutinib—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00021	0.00227	CcSEcCtD
Bosutinib—Headache—Teniposide—lymphatic system cancer	0.00021	0.00226	CcSEcCtD
Bosutinib—Pruritus—Fludarabine—lymphatic system cancer	0.000209	0.00225	CcSEcCtD
Bosutinib—Back pain—Mitoxantrone—lymphatic system cancer	0.000208	0.00224	CcSEcCtD
Bosutinib—Leukopenia—Carmustine—lymphatic system cancer	0.000207	0.00223	CcSEcCtD
Bosutinib—Anaemia—Vincristine—lymphatic system cancer	0.000204	0.0022	CcSEcCtD
Bosutinib—Diarrhoea—Fludarabine—lymphatic system cancer	0.000202	0.00217	CcSEcCtD
Bosutinib—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000199	0.00215	CcSEcCtD
Bosutinib—Nausea—Teniposide—lymphatic system cancer	0.000199	0.00215	CcSEcCtD
Bosutinib—Anaemia—Mitoxantrone—lymphatic system cancer	0.000199	0.00214	CcSEcCtD
Bosutinib—Leukopenia—Vincristine—lymphatic system cancer	0.000197	0.00213	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000197	0.00212	CcSEcCtD
Bosutinib—Chest pain—Carmustine—lymphatic system cancer	0.000197	0.00212	CcSEcCtD
Bosutinib—Myalgia—Carmustine—lymphatic system cancer	0.000197	0.00212	CcSEcCtD
Bosutinib—Malaise—Mitoxantrone—lymphatic system cancer	0.000194	0.00209	CcSEcCtD
Bosutinib—LCK—B Cell Receptor Signaling Pathway—BCL6—lymphatic system cancer	0.000194	0.013	CbGpPWpGaD
Bosutinib—Dyspnoea—Bleomycin—lymphatic system cancer	0.000193	0.00208	CcSEcCtD
Bosutinib—Renal failure acute—Methotrexate—lymphatic system cancer	0.000193	0.00208	CcSEcCtD
Bosutinib—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000192	0.00207	CcSEcCtD
Bosutinib—Oedema—Carmustine—lymphatic system cancer	0.000189	0.00203	CcSEcCtD
Bosutinib—Decreased appetite—Bleomycin—lymphatic system cancer	0.000188	0.00202	CcSEcCtD
Bosutinib—Myalgia—Vincristine—lymphatic system cancer	0.000188	0.00202	CcSEcCtD
Bosutinib—Cough—Mitoxantrone—lymphatic system cancer	0.000187	0.00202	CcSEcCtD
Bosutinib—Infection—Carmustine—lymphatic system cancer	0.000187	0.00202	CcSEcCtD
Bosutinib—Vomiting—Fludarabine—lymphatic system cancer	0.000187	0.00202	CcSEcCtD
Bosutinib—Rash—Fludarabine—lymphatic system cancer	0.000186	0.002	CcSEcCtD
Bosutinib—Dermatitis—Fludarabine—lymphatic system cancer	0.000186	0.002	CcSEcCtD
Bosutinib—Pain—Bleomycin—lymphatic system cancer	0.000185	0.00199	CcSEcCtD
Bosutinib—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000185	0.00199	CcSEcCtD
Bosutinib—Headache—Fludarabine—lymphatic system cancer	0.000185	0.00199	CcSEcCtD
Bosutinib—Myalgia—Mitoxantrone—lymphatic system cancer	0.000183	0.00197	CcSEcCtD
Bosutinib—Chest pain—Mitoxantrone—lymphatic system cancer	0.000183	0.00197	CcSEcCtD
Bosutinib—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000183	0.00197	CcSEcCtD
Bosutinib—Discomfort—Mitoxantrone—lymphatic system cancer	0.000181	0.00195	CcSEcCtD
Bosutinib—Oedema—Vincristine—lymphatic system cancer	0.00018	0.00194	CcSEcCtD
Bosutinib—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00018	0.00194	CcSEcCtD
Bosutinib—Infection—Vincristine—lymphatic system cancer	0.000179	0.00193	CcSEcCtD
Bosutinib—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000178	0.00192	CcSEcCtD
Bosutinib—Nervous system disorder—Vincristine—lymphatic system cancer	0.000177	0.0019	CcSEcCtD
Bosutinib—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000176	0.0019	CcSEcCtD
Bosutinib—CHEK2—Vinblastine—Vincristine—lymphatic system cancer	0.000176	0.0491	CbGdCrCtD
Bosutinib—Oedema—Mitoxantrone—lymphatic system cancer	0.000175	0.00189	CcSEcCtD
Bosutinib—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000175	0.00189	CcSEcCtD
Bosutinib—Nausea—Fludarabine—lymphatic system cancer	0.000175	0.00189	CcSEcCtD
Bosutinib—Infection—Mitoxantrone—lymphatic system cancer	0.000174	0.00188	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000172	0.00185	CcSEcCtD
Bosutinib—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000172	0.00185	CcSEcCtD
Bosutinib—Urticaria—Bleomycin—lymphatic system cancer	0.000172	0.00185	CcSEcCtD
Bosutinib—Body temperature increased—Bleomycin—lymphatic system cancer	0.000171	0.00184	CcSEcCtD
Bosutinib—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00017	0.00184	CcSEcCtD
Bosutinib—VRK2—Cell Cycle—NPM1—lymphatic system cancer	0.000169	0.0113	CbGpPWpGaD
Bosutinib—Dyspnoea—Carmustine—lymphatic system cancer	0.000168	0.00181	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000164	0.00177	CcSEcCtD
Bosutinib—Decreased appetite—Carmustine—lymphatic system cancer	0.000164	0.00177	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000163	0.00176	CcSEcCtD
Bosutinib—Pain—Carmustine—lymphatic system cancer	0.000161	0.00174	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00016	0.00172	CcSEcCtD
Bosutinib—Decreased appetite—Vincristine—lymphatic system cancer	0.000157	0.00169	CcSEcCtD
Bosutinib—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000156	0.00169	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000155	0.00168	CcSEcCtD
Bosutinib—Feeling abnormal—Carmustine—lymphatic system cancer	0.000155	0.00168	CcSEcCtD
Bosutinib—Fatigue—Vincristine—lymphatic system cancer	0.000155	0.00167	CcSEcCtD
Bosutinib—Asthenia—Bleomycin—lymphatic system cancer	0.000155	0.00167	CcSEcCtD
Bosutinib—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000154	0.00166	CcSEcCtD
Bosutinib—Pain—Vincristine—lymphatic system cancer	0.000154	0.00166	CcSEcCtD
Bosutinib—Pruritus—Bleomycin—lymphatic system cancer	0.000153	0.00165	CcSEcCtD
Bosutinib—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000152	0.00164	CcSEcCtD
Bosutinib—Fatigue—Mitoxantrone—lymphatic system cancer	0.000151	0.00163	CcSEcCtD
Bosutinib—Pain—Mitoxantrone—lymphatic system cancer	0.00015	0.00162	CcSEcCtD
Bosutinib—EGFR—Direct p53 effectors—BCL6—lymphatic system cancer	0.00015	0.01	CbGpPWpGaD
Bosutinib—Abdominal pain—Carmustine—lymphatic system cancer	0.000149	0.00161	CcSEcCtD
Bosutinib—Body temperature increased—Carmustine—lymphatic system cancer	0.000149	0.00161	CcSEcCtD
Bosutinib—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000147	0.00159	CcSEcCtD
Bosutinib—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000147	0.00159	CcSEcCtD
Bosutinib—Pancytopenia—Methotrexate—lymphatic system cancer	0.000146	0.00157	CcSEcCtD
Bosutinib—HCK—HIV Infection—NPM1—lymphatic system cancer	0.000145	0.00971	CbGpPWpGaD
Bosutinib—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000145	0.00156	CcSEcCtD
Bosutinib—Neutropenia—Methotrexate—lymphatic system cancer	0.000144	0.00155	CcSEcCtD
Bosutinib—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000143	0.00155	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000143	0.00154	CcSEcCtD
Bosutinib—Abdominal pain—Vincristine—lymphatic system cancer	0.000142	0.00153	CcSEcCtD
Bosutinib—Body temperature increased—Vincristine—lymphatic system cancer	0.000142	0.00153	CcSEcCtD
Bosutinib—Urticaria—Mitoxantrone—lymphatic system cancer	0.000139	0.0015	CcSEcCtD
Bosutinib—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000139	0.00149	CcSEcCtD
Bosutinib—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000139	0.00149	CcSEcCtD
Bosutinib—Pneumonia—Methotrexate—lymphatic system cancer	0.000138	0.00149	CcSEcCtD
Bosutinib—Vomiting—Bleomycin—lymphatic system cancer	0.000137	0.00148	CcSEcCtD
Bosutinib—Infestation—Methotrexate—lymphatic system cancer	0.000137	0.00148	CcSEcCtD
Bosutinib—Infestation NOS—Methotrexate—lymphatic system cancer	0.000137	0.00148	CcSEcCtD
Bosutinib—Rash—Bleomycin—lymphatic system cancer	0.000136	0.00147	CcSEcCtD
Bosutinib—Dermatitis—Bleomycin—lymphatic system cancer	0.000136	0.00147	CcSEcCtD
Bosutinib—Asthenia—Carmustine—lymphatic system cancer	0.000135	0.00146	CcSEcCtD
Bosutinib—Renal failure—Methotrexate—lymphatic system cancer	0.000135	0.00145	CcSEcCtD
Bosutinib—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00013	0.0014	CcSEcCtD
Bosutinib—Asthenia—Vincristine—lymphatic system cancer	0.000129	0.00139	CcSEcCtD
Bosutinib—Diarrhoea—Carmustine—lymphatic system cancer	0.000129	0.00139	CcSEcCtD
Bosutinib—Nausea—Bleomycin—lymphatic system cancer	0.000128	0.00138	CcSEcCtD
Bosutinib—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000128	0.00138	CcSEcCtD
Bosutinib—Asthenia—Mitoxantrone—lymphatic system cancer	0.000126	0.00136	CcSEcCtD
Bosutinib—Dizziness—Carmustine—lymphatic system cancer	0.000125	0.00134	CcSEcCtD
Bosutinib—Diarrhoea—Vincristine—lymphatic system cancer	0.000123	0.00133	CcSEcCtD
Bosutinib—Hepatitis—Methotrexate—lymphatic system cancer	0.000123	0.00133	CcSEcCtD
Bosutinib—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000121	0.00131	CcSEcCtD
Bosutinib—WEE1—Cell Cycle—NPM1—lymphatic system cancer	0.000121	0.00811	CbGpPWpGaD
Bosutinib—Urethral disorder—Methotrexate—lymphatic system cancer	0.000121	0.0013	CcSEcCtD
Bosutinib—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00012	0.00129	CcSEcCtD
Bosutinib—Vomiting—Carmustine—lymphatic system cancer	0.00012	0.00129	CcSEcCtD
Bosutinib—FYN—Host Interactions of HIV factors—NPM1—lymphatic system cancer	0.000119	0.00799	CbGpPWpGaD
Bosutinib—Dizziness—Vincristine—lymphatic system cancer	0.000119	0.00128	CcSEcCtD
Bosutinib—Rash—Carmustine—lymphatic system cancer	0.000119	0.00128	CcSEcCtD
Bosutinib—Dermatitis—Carmustine—lymphatic system cancer	0.000119	0.00128	CcSEcCtD
Bosutinib—Headache—Carmustine—lymphatic system cancer	0.000118	0.00127	CcSEcCtD
Bosutinib—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000116	0.00125	CcSEcCtD
Bosutinib—PKMYT1—Cell Cycle—NPM1—lymphatic system cancer	0.000115	0.00772	CbGpPWpGaD
Bosutinib—Tinnitus—Methotrexate—lymphatic system cancer	0.000115	0.00124	CcSEcCtD
Bosutinib—Vomiting—Vincristine—lymphatic system cancer	0.000114	0.00123	CcSEcCtD
Bosutinib—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000114	0.00123	CcSEcCtD
Bosutinib—Rash—Vincristine—lymphatic system cancer	0.000114	0.00122	CcSEcCtD
Bosutinib—Dermatitis—Vincristine—lymphatic system cancer	0.000113	0.00122	CcSEcCtD
Bosutinib—Headache—Vincristine—lymphatic system cancer	0.000113	0.00122	CcSEcCtD
Bosutinib—Nausea—Carmustine—lymphatic system cancer	0.000112	0.00121	CcSEcCtD
Bosutinib—Vomiting—Mitoxantrone—lymphatic system cancer	0.000111	0.0012	CcSEcCtD
Bosutinib—Immune system disorder—Methotrexate—lymphatic system cancer	0.000111	0.0012	CcSEcCtD
Bosutinib—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000111	0.00119	CcSEcCtD
Bosutinib—Rash—Mitoxantrone—lymphatic system cancer	0.000111	0.00119	CcSEcCtD
Bosutinib—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00011	0.00119	CcSEcCtD
Bosutinib—Headache—Mitoxantrone—lymphatic system cancer	0.00011	0.00118	CcSEcCtD
Bosutinib—Malnutrition—Methotrexate—lymphatic system cancer	0.000107	0.00115	CcSEcCtD
Bosutinib—Nausea—Vincristine—lymphatic system cancer	0.000107	0.00115	CcSEcCtD
Bosutinib—Dysgeusia—Methotrexate—lymphatic system cancer	0.000105	0.00113	CcSEcCtD
Bosutinib—Nausea—Mitoxantrone—lymphatic system cancer	0.000104	0.00112	CcSEcCtD
Bosutinib—Back pain—Methotrexate—lymphatic system cancer	0.000104	0.00112	CcSEcCtD
Bosutinib—LCK—Host Interactions of HIV factors—NPM1—lymphatic system cancer	9.94e-05	0.00665	CbGpPWpGaD
Bosutinib—Ill-defined disorder—Methotrexate—lymphatic system cancer	9.93e-05	0.00107	CcSEcCtD
Bosutinib—Anaemia—Methotrexate—lymphatic system cancer	9.89e-05	0.00107	CcSEcCtD
Bosutinib—Malaise—Methotrexate—lymphatic system cancer	9.65e-05	0.00104	CcSEcCtD
Bosutinib—Leukopenia—Methotrexate—lymphatic system cancer	9.58e-05	0.00103	CcSEcCtD
Bosutinib—Cough—Methotrexate—lymphatic system cancer	9.34e-05	0.00101	CcSEcCtD
Bosutinib—Chest pain—Methotrexate—lymphatic system cancer	9.11e-05	0.000982	CcSEcCtD
Bosutinib—Arthralgia—Methotrexate—lymphatic system cancer	9.11e-05	0.000982	CcSEcCtD
Bosutinib—Myalgia—Methotrexate—lymphatic system cancer	9.11e-05	0.000982	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	9.05e-05	0.000976	CcSEcCtD
Bosutinib—Discomfort—Methotrexate—lymphatic system cancer	9e-05	0.000971	CcSEcCtD
Bosutinib—CHEK2—Cell Cycle—NPM1—lymphatic system cancer	8.8e-05	0.00589	CbGpPWpGaD
Bosutinib—Anaphylactic shock—Methotrexate—lymphatic system cancer	8.74e-05	0.000942	CcSEcCtD
Bosutinib—ABCB1—HIF-1-alpha transcription factor network—NPM1—lymphatic system cancer	8.73e-05	0.00585	CbGpPWpGaD
Bosutinib—Infection—Methotrexate—lymphatic system cancer	8.68e-05	0.000936	CcSEcCtD
Bosutinib—Nervous system disorder—Methotrexate—lymphatic system cancer	8.57e-05	0.000924	CcSEcCtD
Bosutinib—Thrombocytopenia—Methotrexate—lymphatic system cancer	8.55e-05	0.000922	CcSEcCtD
Bosutinib—Skin disorder—Methotrexate—lymphatic system cancer	8.49e-05	0.000915	CcSEcCtD
Bosutinib—PHKG1—Disease—NPM1—lymphatic system cancer	8.06e-05	0.00539	CbGpPWpGaD
Bosutinib—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	7.96e-05	0.000858	CcSEcCtD
Bosutinib—CDK2—Cell Cycle—NPM1—lymphatic system cancer	7.94e-05	0.00532	CbGpPWpGaD
Bosutinib—Dyspnoea—Methotrexate—lymphatic system cancer	7.79e-05	0.00084	CcSEcCtD
Bosutinib—FYN—HIV Infection—NPM1—lymphatic system cancer	7.76e-05	0.00519	CbGpPWpGaD
Bosutinib—Decreased appetite—Methotrexate—lymphatic system cancer	7.6e-05	0.000819	CcSEcCtD
Bosutinib—CSNK1E—Cell Cycle—NPM1—lymphatic system cancer	7.55e-05	0.00505	CbGpPWpGaD
Bosutinib—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	7.54e-05	0.000813	CcSEcCtD
Bosutinib—Fatigue—Methotrexate—lymphatic system cancer	7.53e-05	0.000812	CcSEcCtD
Bosutinib—Pain—Methotrexate—lymphatic system cancer	7.47e-05	0.000805	CcSEcCtD
Bosutinib—Feeling abnormal—Methotrexate—lymphatic system cancer	7.2e-05	0.000776	CcSEcCtD
Bosutinib—Gastrointestinal pain—Methotrexate—lymphatic system cancer	7.14e-05	0.00077	CcSEcCtD
Bosutinib—Urticaria—Methotrexate—lymphatic system cancer	6.94e-05	0.000748	CcSEcCtD
Bosutinib—Body temperature increased—Methotrexate—lymphatic system cancer	6.91e-05	0.000744	CcSEcCtD
Bosutinib—Abdominal pain—Methotrexate—lymphatic system cancer	6.91e-05	0.000744	CcSEcCtD
Bosutinib—BCR—Disease—NPM1—lymphatic system cancer	6.57e-05	0.0044	CbGpPWpGaD
Bosutinib—LCK—HIV Infection—NPM1—lymphatic system cancer	6.46e-05	0.00432	CbGpPWpGaD
Bosutinib—Asthenia—Methotrexate—lymphatic system cancer	6.27e-05	0.000676	CcSEcCtD
Bosutinib—Pruritus—Methotrexate—lymphatic system cancer	6.18e-05	0.000666	CcSEcCtD
Bosutinib—Diarrhoea—Methotrexate—lymphatic system cancer	5.98e-05	0.000644	CcSEcCtD
Bosutinib—Dizziness—Methotrexate—lymphatic system cancer	5.78e-05	0.000623	CcSEcCtD
Bosutinib—Vomiting—Methotrexate—lymphatic system cancer	5.56e-05	0.000599	CcSEcCtD
Bosutinib—Rash—Methotrexate—lymphatic system cancer	5.51e-05	0.000594	CcSEcCtD
Bosutinib—Dermatitis—Methotrexate—lymphatic system cancer	5.5e-05	0.000593	CcSEcCtD
Bosutinib—Headache—Methotrexate—lymphatic system cancer	5.47e-05	0.00059	CcSEcCtD
Bosutinib—Nausea—Methotrexate—lymphatic system cancer	5.19e-05	0.000559	CcSEcCtD
Bosutinib—PRKCQ—Disease—NPM1—lymphatic system cancer	4.79e-05	0.00321	CbGpPWpGaD
Bosutinib—CSNK1A1—Disease—NPM1—lymphatic system cancer	4.79e-05	0.00321	CbGpPWpGaD
Bosutinib—CSK—Disease—NPM1—lymphatic system cancer	4.63e-05	0.0031	CbGpPWpGaD
Bosutinib—CSNK1E—Disease—NPM1—lymphatic system cancer	3.87e-05	0.00259	CbGpPWpGaD
Bosutinib—HCK—Disease—NPM1—lymphatic system cancer	3.55e-05	0.00238	CbGpPWpGaD
Bosutinib—ERBB4—Disease—NPM1—lymphatic system cancer	3.35e-05	0.00224	CbGpPWpGaD
Bosutinib—ERBB3—Disease—NPM1—lymphatic system cancer	2.95e-05	0.00197	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—NPM1—lymphatic system cancer	2.02e-05	0.00135	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—NPM1—lymphatic system cancer	1.97e-05	0.00132	CbGpPWpGaD
Bosutinib—FYN—Disease—NPM1—lymphatic system cancer	1.9e-05	0.00127	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—NPM1—lymphatic system cancer	1.89e-05	0.00127	CbGpPWpGaD
Bosutinib—EGFR—Disease—NPM1—lymphatic system cancer	1.64e-05	0.0011	CbGpPWpGaD
Bosutinib—LCK—Disease—NPM1—lymphatic system cancer	1.58e-05	0.00106	CbGpPWpGaD
Bosutinib—SRC—Disease—NPM1—lymphatic system cancer	1.4e-05	0.000938	CbGpPWpGaD
